Everseen vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Everseen is the leading Vision AI platform for retail loss prevention; monitors 140,000+ checkouts globally for 11 of the top 20 retailers; processes 6 petabytes of video daily; partnered with Google Cloud at NRF 2025.
About
Everseen is a Dublin-headquartered AI company that deploys computer vision technology to reduce shrink, fraud, and operational inefficiency at retail checkpoints. Its Evercheck product monitors self-checkout and point-of-sale systems in real time, identifying over 30 unique fraud and loss patterns including non-scan incidents, cart-based theft, and scan errors. As of 2025, Everseen''s platform monitors more than 140,000 checkout lanes, captures over 15 million customer interactions daily, and processes 6 petabytes of video data per day — making it the dominant scale player in retail Vision AI.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.